There's Reason For Concern Over Nektar Therapeutics' (NASDAQ:NKTR) Massive 26% Price Jump
Nektar Therapeutics' (NASDAQ:NKTR) Large Institutional Owners Must Be Happy as Stock Continues to Impress, up 13% Over the Past Week
Rodman & Renshaw Initiates Nektar Therapeutics(NKTR.US) With Buy Rating, Announces Target Price $2
Oppenheimer Maintains Nektar Therapeutics(NKTR.US) With Hold Rating
Nektar Therapeutics(NKTR.US) Director Sells US$23,400 in Common Stock
Express News | Nektar Therapeutics - Ind-Enabling Studies Underway for Nktr-0165 With First-in-Human Studies Planned in First Half of 2025
Express News | Nektar Therapeutics: Nktr-0165 Demonstrates Selective Enhancement of Treg Cell Function Through Novel Agonistic Mechanism
Express News | Nektar Therapeutics Presents First Preclinical Data on Nktr-0165, a Tnfr2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at Eular 2024
Nektar, Verastem Among Healthcare Additions in Russell Microcap; Assertio, Sangamo Removed
Russell 3000: Inovio, Ocugen Among Healthcare Additions; Assertio, Ginkgo Bioworks Among Deletions
Nektar Management to Present at Upcoming Investor Conferences
Nektar Files to Sell 25M Shares of Common Stock for Holders
J.P. Morgan Maintains Nektar Therapeutics(NKTR.US) With Sell Rating
Analysts Conflicted on These Healthcare Names: Nektar Therapeutics (NKTR) and BioNTech SE (BNTX)
Nektar Therapeutics(NKTR.US) 10% Shareholder Sells US$99,629.6 in Common Stock
Nektar Therapeutics (NKTR) First Quarter 2024 Earnings Overview
Nektar Therapeutics | 10-Q: Quarterly report
Express News | Nektar Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results
Q1 2024 Nektar Therapeutics Earnings Call
Earnings Call Summary | Nektar Therapeutics(NKTR.US) Q1 2024 Earnings Conference